[{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CAP-1002","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Johns Hopkins University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"LSNME\/SW1","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Johns Hopkins University","highestDevelopmentStatusID":"4","companyTruncated":"Capricor Therapeutics \/ Johns Hopkins University"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Capricor","highestDevelopmentStatusID":"8","companyTruncated":"Capricor Therapeutics \/ Capricor"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Allogeneic Cardiosphere-derived Cell Therapy","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Capricor Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Capricor Therapeutics"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"STX-N","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CAP-1002","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Allogeneic Cardiac-derived Cell Therapy","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.73999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.73999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Allogeneic Cardiosphere-derived Cell","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CAP-1002","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"CAP-1002","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CAP-1002","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Exosome-based Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Capricor Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CAP-1002","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cell","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cell","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cell","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0.73999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Piper Sandler & Co","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Piper Sandler & Co"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Piper Sandler & Co","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Piper Sandler & Co"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Deramiocel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Capricor Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Piper Sandler & Co","highestDevelopmentStatusID":"14","companyTruncated":"Capricor Therapeutics \/ Piper Sandler & Co"}]
Find Clinical Drug Pipeline Developments & Deals by Capricor Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
